Erasca (NASDAQ: ERAS) narrows ERAS-0015 Phase 1 data window

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Erasca, Inc. updated the expected timing for initial Phase 1 monotherapy data from its pan-RAS molecular glue ERAS-0015, now guiding that data from the AURORAS-1 and JYP0015M101 trials will be available no later than mid-May 2026, compared with its prior expectation of the first half of 2026.

AURORAS-1 is evaluating ERAS-0015 in patients with RAS-mutant solid tumors, while licensor Guangzhou Joyo Pharmatech Co., Ltd. is running JYP0015M101 in China in patients with advanced solid tumors harboring specific RAS mutations. The company also highlights typical forward-looking statement risks and directs readers to its risk factor disclosures.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Latest data readout timing: no later than mid-May 2026 Prior data timing guidance: first half of 2026

2 metrics

Latest data readout timing no later than mid-May 2026 Phase 1 monotherapy data for ERAS-0015 from AURORAS-1 and JYP0015M101

Prior data timing guidance first half of 2026 Earlier expectation for ERAS-0015 Phase 1 monotherapy data

Key Terms

pan-RAS molecular glue, AURORAS-1 Phase 1 trial, JYP0015M101, forward-looking statements, +1 more

5 terms

pan-RAS molecular glue medical

"the Company’s pan-RAS molecular glue ERAS-0015 from the AURORAS-1"

A pan‑RAS molecular glue is a small drug-like molecule designed to stick to RAS proteins and recruit another cellular partner to change or destroy them, and it works across the main RAS family members rather than just one subtype. For investors, this matters because RAS-driven cancers are common and hard to treat, so a broadly active molecular glue could address many tumor types, potentially creating a large market opportunity while carrying the usual high scientific and regulatory risk of new drug approaches.

AURORAS-1 Phase 1 trial medical

"evaluating ERAS-0015 in the AURORAS-1 Phase 1 trial in patients"

JYP0015M101 medical

"Joyo), is evaluating ERAS-0015 in the JYP0015M101 trial in China"

forward-looking statements regulatory

"statements contained in this report regarding matters that are not historical facts are forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Risk Factors regulatory

"including under the heading “Risk Factors” in its annual report on Form 10-K"

Risk factors are elements or conditions that could cause an investment's value to decrease or lead to potential losses. They are like warning signs or obstacles that can affect the success of an investment, making it uncertain or more unpredictable. Recognizing risk factors helps investors understand the possible challenges and make more informed decisions.

Understanding 8-K Material Events →

04/21/2026 - 09:10 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): April 21, 2026

    

Erasca, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-40602	83-1217027
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3115 Merryfield Row Suite 300
San Diego, California		92121
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: (858) 465-6511

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	ERAS	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On April 21, 2026, Erasca, Inc. (the “Company”) narrowed the time period for the anticipated Phase 1 monotherapy data readout for the Company’s pan-RAS molecular glue ERAS-0015 from the AURORAS-1 and JYP0015M101 clinical trials to no later than mid-May of 2026, from the prior guidance of the first half of 2026. The Company is evaluating ERAS-0015 in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors, and the Company’s licensor, Guangzhou Joyo Pharmatech Co., Ltd. (Joyo), is evaluating ERAS-0015 in the JYP0015M101 trial in China in patients with advanced solid tumors harboring specific RAS mutations.

Forward-Looking Statements

The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the Company’s current beliefs and expectations and include, but are not limited to statements regarding the timing of the anticipated data readout of the AURORAS-1 and JYP0015M101 clinical trials. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Company’s business, including, without limitation the risks described in the Company’s prior filings with the SEC, including under the heading “Risk Factors” in its annual report on Form 10-K for the year ended December 31, 2025, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			Erasca, Inc.

Date:	April 21, 2026	By:	/s/ Ebun Garner
			Chief Legal Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Erasca (ERAS) announce in this 8-K filing?

Erasca updated the timing for Phase 1 monotherapy data from ERAS-0015. The company now expects data from the AURORAS-1 and JYP0015M101 trials no later than mid-May 2026, tightening prior guidance of a first-half 2026 readout.

What is ERAS-0015 in Erasca’s (ERAS) pipeline?

ERAS-0015 is described as a pan-RAS molecular glue being developed for solid tumors. It is being tested as monotherapy in RAS-mutant solid tumors in the AURORAS-1 Phase 1 trial and in advanced solid tumors with specific RAS mutations in China.

Which clinical trials are included in Erasca’s ERAS-0015 timing update?

The timing update covers two Phase 1 monotherapy trials: AURORAS-1, sponsored by Erasca in RAS-mutant solid tumors, and JYP0015M101, conducted in China by licensor Guangzhou Joyo Pharmatech in advanced solid tumors with specific RAS mutations.

How did Erasca (ERAS) change its guidance for ERAS-0015 data readout?

Erasca narrowed its guidance from a broad "first half of 2026" window to expecting ERAS-0015 Phase 1 monotherapy data no later than mid-May 2026. This provides a more specific near-term timing for the upcoming clinical data release.

What risks does Erasca (ERAS) highlight regarding the ERAS-0015 data timing?

Erasca notes that forward-looking statements about the ERAS-0015 data timing involve risks and uncertainties. It points investors to existing risk factor discussions in its Form 10-K for the year ended December 31, 2025, and subsequent SEC filings.

Who is Erasca’s partner in the JYP0015M101 ERAS-0015 trial?

The JYP0015M101 trial is run by Guangzhou Joyo Pharmatech Co., Ltd., Erasca’s licensor for ERAS-0015. Joyo is evaluating ERAS-0015 in patients in China with advanced solid tumors that carry specific RAS mutations, complementing Erasca’s AURORAS-1 study.

Filing Exhibits & Attachments

1 document